Robert F Kennedy Jr is distancing himself from his anti-vaccine work as he seeks to become the leader of the nation's top health agency under President Donald Trump, according to government ethics documents released on Wednesday.
Kennedy has pulled in roughly $10 million in income from his work over the past year, which includes speaking fees, leading an anti-vaccine nonprofit and legal fees, government ethics forms filed for his nomination show. He has millions of dollars more tied up in investments and other assets.
If confirmed, he has promised to stop collecting fees on some of his vaccine lawsuits involving the US government.
Kennedy is a lawyer who has worked on lawsuits involving environmental and vaccine injury claims against some of the country's biggest companies. He also said he would forgo payment from claims against the US under the National Vaccine Injury Compensation programme.
A spokesperson for Kennedy did not immediately respond to a request for comment about the filing.
As of December, Kennedy said in the filing that he is no longer serving as chairman or chief legal counsel for Children's Health Defense, his nonprofit that launched lawsuits against the federal government over vaccines, including the authorisation of the Covid-19 shot in children. He previously made a $326,000 salary for three months of work at the nonprofit in 2023.
But he will still benefit in other ways from his anti-vaccine advocacy, which has spanned several years. Compensation will continue to flow into Kennedy's bank accounts from referral fees for legal cases that don't involve the US government, including fees he collects from a law firm that's sued Merck over Gardasil, its human papillomavirus vaccine that prevents cervical cancer.
Last year, he made over $850,000 from the arrangement.
He will also still get royalties from books he's written, some of which have spread falsehoods about vaccine safety and other health issues.
Kennedy said he expects at least $2 million in advances for two forthcoming books, though he said he would not promote or do further work on those titles if confirmed.
Despite his criticism of the pharmaceutical industry, Kennedy also holds investments in biotech industries, which he would regulate if confirmed to lead the Health and Human Services Department.
Kennedy says he plans to divest as much as $50,000 with Dragonfly Therapeutics, a pharmaceutical company that develops cancer drugs, as well as up to $15,000 he has in CRISPR Therapeutics, a gene-editing technology.
A Senate finance committee hearing for Kennedy is scheduled for later this month. The lawyer-turned-politician was seen around Washington in recent days, joining in on festivities for Trump's inauguration.
He even hosted his own "Make America Healthy Again" ball on the day Trump was sworn in.
"MAHA" has become a popular slogan among Trump and Kennedy loyalists alike.
And that's another thing Kennedy reports he's profited from in his ethics filing -- MAHA merchandise, which has made him $100,000.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)